Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
about
Frontiers in Toxicogenomics in the Twenty-First Century-the Grand Challenge: To Understand How the Genome and Epigenome Interact with the Toxic Environment at the Single-Cell, Whole-Organism, and Multi-Generational Level.Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
P2860
Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Cardiac safety of non-anthracy ...... r HER2-positive breast cancer.
@en
type
label
Cardiac safety of non-anthracy ...... r HER2-positive breast cancer.
@en
prefLabel
Cardiac safety of non-anthracy ...... r HER2-positive breast cancer.
@en
P2093
P2860
P1476
Cardiac safety of non-anthracy ...... r HER2-positive breast cancer.
@en
P2093
Anthony F Yu
Chau T Dang
Clifford A Hudis
Jennifer E Liu
Kevin C Oeffinger
Richard M Steingart
Roy B Mukku
Shivani Verma
P2860
P2888
P356
10.1007/S10549-017-4362-X
P407
P577
2017-07-14T00:00:00Z
P6179
1090674618